According to Precedence Research, during the forecast period of 2022 to 2030, the global psoriasis treatment market is estimated to develop at a compound annual growth rate (CAGR) of 8.16%. The global psoriasis treatment market was valued at USD 25.3 billion in 2021, and it is predicted to exceed USD 51.24 billion by 2030. The study investigates several elements and their consequences on the growth of the psoriasis treatment market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/2034
This report focuses on psoriasis treatment market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall psoriasis treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Report Scope of the Psoriasis Treatment Market
Report Coverage | Details |
Market Size in 2022 | USD 27.36 Billion |
Market Size by 2030 | USD 51.24 Billion |
Growth Rate from 2022 to 2030 | CAGR of 8.16% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segments Covered | Drug Class, Treatment Type, Type, Route of Administration, Distribution Channel, Geography |
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of psoriasis treatment, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of psoriasis treatment has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the psoriasis treatment market.
Some of the prominent players in the psoriasis treatment market include:
- Johnson & Johnson Services, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Novartis AG (Switzerland)
- LEO Pharma A/S (Denmark)
- Merck & Co., Inc. (U.S.)
- UCB S.A. (Belgium)
- Sun Pharmaceutical Industries Ltd. (India)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Evelo Biosciences, Inc. (U.S.)
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/2034
Segments Covered in the Report
By Drug Class
- Interleukins
- TNF Inhibitors
- Others
By Treatment Type
- Biologic Drugs
- Small Molecule Systemic Drugs
- Tropical Therapies
By Type
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
By Route of Administration
- Oral
- Parenteral
- Topical
By Distribution Channel
- Hospital Pharmacies
- Online pharmacies
- Retail Pharmacies
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Psoriasis Treatment Market
5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Psoriasis Treatment Market, By Drug Class
8.1. Psoriasis Treatment Market, by Drug Class, 2022-2030
8.1.1. Interleukins
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. TNF Inhibitors
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Psoriasis Treatment Market, By Treatment Type
9.1. Psoriasis Treatment Market, by Treatment Type, 2022-2030
9.1.1. Biologic Drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Small Molecule Systemic Drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Tropical Therapies
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Psoriasis Treatment Market, By Type
10.1. Psoriasis Treatment Market, by Type, 2022-2030
10.1.1. Psoriatic Arthritis
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Plaque Psoriasis
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Psoriasis Treatment Market, By Route of Administration
11.1. Psoriasis Treatment Market, by Route of Administration, 2022-2030
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Topical
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Psoriasis Treatment Market, By Distribution Channel
12.1. Psoriasis Treatment Market, by Distribution Channel, 2022-2030
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Online pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Retail Pharmacies
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Psoriasis Treatment Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. Johnson & Johnson Services, Inc. (U.S.)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer Inc. (U.S.)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AbbVie Inc. (U.S.)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Novartis AG (Switzerland)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. LEO Pharma A/S (Denmark)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co., Inc. (U.S.)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. UCB S.A. (Belgium)
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sun Pharmaceutical Industries Ltd. (India)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Amgen Inc. (U.S.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eli Lilly and Company (U.S.)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/2034
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com